CompletedPhase 3NCT01146951

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Studying Lennox-Gastaut syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eisai Limited
Principal Investigator
Hiroki Takano
Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
Intervention
Rufinamide (E2080)(drug)
Enrollment
66 enrolled
Eligibility
4-30 years · All sexes
Timeline
20102011

Study locations (23)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01146951 on ClinicalTrials.gov

Other trials for Lennox-Gastaut syndrome

Additional recruiting or active studies for the same condition.

See all trials for Lennox-Gastaut syndrome

← Back to all trials